Nanoapproaches to Modifying Epigenetics of Epithelial Mesenchymal Transition for Treatment of Pulmonary Fibrosis

Medicine and Dentistry

• Mesenchymal-Epithelial Transition 100%
• Idiopathic Pulmonary Fibrosis 80%
• Nanoparticle 60%
• Epigenomics 60%
• Obstetric Delivery 60%
• Therapeutic Procedure 60%
• Myofibroblast 60%
• Combination Therapy 40%
• Nanomedicine 40%
• Mortality 40%
• Fibrosis 20%
• Protein 20%
• Toxicity 20%
• Extracellular Matrix 20%
• Gene Expression 20%
• Epithelial Cell 20%
• Morbidity 20%
• Deterioration 20%
• Liposome 20%
• Histone Acetylation 20%
• Exosome 20%
• Silo-Filler's Disease 20%
• Injury 20%
• Pulmonary Fibrosis 20%
• Nintedanib 20%
• Pirfenidone 20%
• Survival 20%
• Lung 20%
• Incidence 20%
• Lung Function 20%

Pharmacology, Toxicology and Pharmaceutical Science

• Fibrosing Alveolitis 80%
• Nanomedicine 40%
• Mortality 40%
• Controlled Release 40%
• Protein 20%
• Toxicity 20%
• Liposome 20%
• Fibrosis 20%
• Morbidity 20%
• Lung Disease 20%
• Injury 20%
• Lung Fibrosis 20%
• Survival 20%
• Incidence 20%
• Pirfenidone 20%
• Nintedanib 20%

Biochemistry, Genetics and Molecular Biology

• Mesenchymal-Epithelial Transition 100%
• Myofibroblast 60%
• Epigenetics 60%
• Mortality 40%
• Gene Expression 20%
• Polymerization 20%
• Histone Acetylation 20%
• Morbidity 20%
• Bromodomain 20%
• Protein 20%
• Survival 20%
• Incidence 20%
• Lung Function 20%